Valneva SE
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VLA.PA research report →
About the company
Valneva SE is a specialized biotechnology company focused on developing and bringing to market preventative vaccines for infectious diseases with significant unmet medical needs. Their commercial offerings for travelers include IXIARO, a vaccine against Japanese encephalitis, and DUKORAL, an oral vaccine designed to protect against diarrhea caused by Vibrio cholera and specific heat-labile toxin-producing Enterotoxigenic Escherichia coli. The company also progressed VLA2001, a vaccine candidate targeting SARS-CoV-2.
- CEO
- Thomas Lingelbach
- IPO
- 2007
- Employees
- 713
- HQ
- Saint-Herblain, FR
Price Chart
- Market Cap
- $430.69M
- P/E
- -2.80
- P/S
- 2.75
- P/B
- 5.10
- EV/EBITDA
- -6.18
- Div Yield
- 0.00%
- Gross Margin
- 29.46%
- Op Margin
- -68.81%
- Net Margin
- -88.30%
- ROE
- -106.22%
- ROIC
- -36.00%
- Revenue
- $174.66M · 3.00%
- Net Income
- $-115,192,000 · -840.57%
- EPS
- $-0.68 · -708.56%
- Op Income
- $-81,631,000
- FCF YoY
- 31.42%
- 52W High
- $5.42
- 52W Low
- $2.13
- 50D MA
- $2.44
- 200D MA
- $3.63
- Beta
- 1.40
- Avg Volume
- 1.01M
Get TickerSpark's AI analysis on VLA.PA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our VLA.PA coverage
Recent articles, reports, and earnings notes.
No research on VLA.PA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VLA.PA report →Similar companies
Peers in the same neighborhood.